Alnylam Pharmaceuticals, Inc. (ALNY) Stock AnalysisALNYAlnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alnylam Pharmaceuticals is a good buy right now due to its recent revenue surge of 74% year-over-year, bringing in $1.17 billion in the latest quarter, and a positive analyst sentiment with 18 out of 21 analysts recommending a buy. The current price of $232.68 is significantly lower than the average analyst price target of $336, suggesting a potential upside of approximately 44%. However, the main risk is the company's high debt-to-equity ratio of 201.69%, which could impact financial stability if not managed carefully.

18 analysts cover ALNY: 13 rate it Buy, 4 Hold and 1 Sell. The average price target is 479.53.